admin – Page 3281 – Get News Story

Cutaneous Lupus Erythematosus Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

The Key Cutaneous Lupus Erythematosus Companies in the market include – Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others.

DelveInsight’s “Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Cutaneous Lupus Erythematosus, offering comprehensive insights into the Cutaneous Lupus Erythematosus revenue trends, prevalence, and treatment landscape. The report delves into key Cutaneous Lupus Erythematosus statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Cutaneous Lupus Erythematosus therapies. Additionally, we cover the landscape of Cutaneous Lupus Erythematosus clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Cutaneous Lupus Erythematosus treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Cutaneous Lupus Erythematosus space.

To Know in detail about the Cutaneous Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous Lupus Erythematosus Market Forecast

Some of the key facts of the Cutaneous Lupus Erythematosus Market Report:

The Cutaneous Lupus Erythematosus market size was valued ~USD 500 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Merck KGaA’s oral TLR7/8 inhibitor, enpatoran, did not achieve its primary endpoint in a subgroup of patients; however, the company plans to continue its development. During the Q4 earnings call, Merck disclosed that enpatoran failed to meet the British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) response at 24 weeks in patients with systemic lupus erythematosus (SLE).
The United States holds the largest market size for Cutaneous Lupus Erythematosus, estimated at approximately USD 400 million, surpassing the markets of EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
In 2023, the total diagnosed prevalent cases of Cutaneous Lupus Erythematosus across the 7MM were approximately 800,000 and are expected to rise throughout the forecast period.

Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
The Cutaneous Lupus Erythematosus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous Lupus Erythematosus pipeline products will significantly revolutionize the Cutaneous Lupus Erythematosus market dynamics.
Chronic Cutaneous Lupus Erythematosus has been found to be more prevalent among the diagnosed population compared to other types in the 7MM. In the United States alone, it accounted for approximately 340,000 cases in 2023.
Within the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent cases, followed by France, while Spain had the lowest, with approximately 40,000 cases.
In 2023, the US represented approximately 60% of all diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) across the 7MM.
Within the EU4 and the UK, the UK reported the highest diagnosed prevalence of Cutaneous Lupus Erythematosus (CLE) in 2023, with approximately 80,000 cases, whereas Spain had the lowest, with around 40,000 cases.
Japan recorded approximately 66,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) in 2023.
In 2023, the United States had approximately 478,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE).

Cutaneous Lupus Erythematosus Overview

Cutaneous Lupus Erythematosus (CLE) is a form of lupus that primarily affects the skin, causing inflammation and various skin lesions. It can occur independently or as part of systemic lupus erythematosus (SLE). CLE is classified into subtypes, including acute, subacute, and chronic forms, with symptoms like rashes, redness, and scaly patches, often triggered by sunlight exposure. The condition can vary in severity and may leave scars or pigmentation changes. Diagnosis involves clinical evaluation, skin biopsy, and laboratory tests. Treatment typically includes sun protection, topical steroids, immunosuppressants, and antimalarial medications to manage symptoms and prevent flare-ups.

Get a Free sample for the Cutaneous Lupus Erythematosus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market

Cutaneous Lupus Erythematosus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cutaneous Lupus Erythematosus Epidemiology Segmentation:

The Cutaneous Lupus Erythematosus market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of CLE in the 7MM
Prevalent cases of CLE by Gender in the 7MM
Prevalent Cases of CLE by Type in the 7MM
Prevalent Cases of CLE by Severity in the 7MM
Total Treated Cases of CLE in the 7MM

Download the report to understand which factors are driving Cutaneous Lupus Erythematosus epidemiology trends @ Cutaneous Lupus Erythematosus Epidemiology Forecast

Cutaneous Lupus Erythematosus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous Lupus Erythematosus market or expected to get launched during the study period. The analysis covers Cutaneous Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cutaneous Lupus Erythematosus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cutaneous Lupus Erythematosus Therapies and Key Companies

Litifilimab: Biogen
Daxdilimab: Horizon Therapeutics
SOTYKTU: Bristol–Myers Squibb
Anifrolumab: AstraZeneca
SAR443122: Sanofi
CC-11050: Amgen
Litifilimab: Biogen
Lanraplenib: Gilead Sciences
PF-06823859: Pfizer
Deucravacitinib: Bristol-Myers Squibb
KRP203: Novartis
R932333: Rigel Pharmaceuticals
M5049: Merck

Discover more about therapies set to grab major Cutaneous Lupus Erythematosus market share @ Cutaneous Lupus Erythematosus Treatment Landscape

Cutaneous Lupus Erythematosus Market Strengths

A growing body of research focused on understanding the pathogenesis of CLE, which could lead to the development of more targeted and effective treatment.
The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols along with improved guidelines. Further, unique features of disease subtypes are being defined.

Cutaneous Lupus Erythematosus Market Opportunities

Research into the pathogenesis of CLE is accelerating, and discoveries are identifying genetic and epigenetic changes. Continued research on mechanisms driving CLE will provide new methods for preventing and treating cutaneous lesions.
The lack of a cure for CLE provides a massive opportunity to launch effective novel therapies and targeted treatments in the emerging pipeline to take over the current market.

Scope of the Cutaneous Lupus Erythematosus Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
Cutaneous Lupus Erythematosus Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and Cutaneous Lupus Erythematosus emerging therapies
Cutaneous Lupus Erythematosus Market Dynamics: Cutaneous Lupus Erythematosus market drivers and Cutaneous Lupus Erythematosus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cutaneous Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Cutaneous Lupus Erythematosus Market Access and Reimbursement

To know more about Cutaneous Lupus Erythematosus companies working in the treatment market, visit @ Cutaneous Lupus Erythematosus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cutaneous Lupus Erythematosus Market Report Introduction

2. Executive Summary for Cutaneous Lupus Erythematosus

3. SWOT analysis of Cutaneous Lupus Erythematosus

4. Cutaneous Lupus Erythematosus Patient Share (%) Overview at a Glance

5. Cutaneous Lupus Erythematosus Market Overview at a Glance

6. Cutaneous Lupus Erythematosus Disease Background and Overview

7. Cutaneous Lupus Erythematosus Epidemiology and Patient Population

8. Country-Specific Patient Population of Cutaneous Lupus Erythematosus

9. Cutaneous Lupus Erythematosus Current Treatment and Medical Practices

10. Cutaneous Lupus Erythematosus Unmet Needs

11. Cutaneous Lupus Erythematosus Emerging Therapies

12. Cutaneous Lupus Erythematosus Market Outlook

13. Country-Wise Cutaneous Lupus Erythematosus Market Analysis (2020–2034)

14. Cutaneous Lupus Erythematosus Market Access and Reimbursement of Therapies

15. Cutaneous Lupus Erythematosus Market Drivers

16. Cutaneous Lupus Erythematosus Market Barriers

17. Cutaneous Lupus Erythematosus Appendix

18. Cutaneous Lupus Erythematosus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous Lupus Erythematosus Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

From SEO to GEO: geocentric.ai Is Redefining Visibility in the AI Era

New startup helps businesses and creators get found, cited, and trusted by ChatGPT, Perplexity, and other AI engines

May 19, 2025 – Brooklyn NY – The way people search has changed—and so have the rules of visibility. Today’s users aren’t scrolling through ten blue links. They’re getting full answers from AI. That’s why geocentric.ai is launching a revolutionary platform that helps websites and creators show up in those answers—not just in traditional search rankings.

geocentric.ai is pioneering a bold new category called GEO: Generative Engine Optimization. Unlike SEO, which was built for search engines like Google, GEO is designed for generative platforms like ChatGPT, Bing Copilot, Google SGE, and Perplexity.ai. These engines don’t just find pages—they write responses, and only cite the most trusted, high-quality sources. geocentric.ai helps you become one of them.Backed by cutting-edge research and science, the platform uses AI-driven audits, optimization tools, and content strategies proven to increase your chances of being cited by LLMs. In fact, studies show that content optimized with GEO methods—like adding statistics, quotes, and schema—can boost AI visibility by up to 40%.

“With generative engines, there are no ads, no rankings, and no way to pay your way in,” said Arik Rozen, co-founder of geocentric.ai.“You either show up in the answer—or you don’t exist. Businesses using geocentric.ai typically see a major uptick in AI-driven traffic within 3 to 6 months. But without GEO, traffic will decline. This is the new front page of the internet—and you have to earn your place in it.

”Getting listed on AI platforms has never been easier thanks to geocentric.ai’s product suite:

geoTracker lets you monitor your current AI visibility score in seconds.

geoPlanner gives you a personalized, science-backed 6-month plan to improve your visibility and get cited by major AI engines.

And for those who want full support,

geoManager is your complete GEO team—executing the plan, optimizing your content, and working 24/7 to boost your presence across platforms.

With packages starting from free all the way to full-service execution, geocentric.ai is making this new form of optimization accessible to everyone—from solopreneurs to enterprise teams. The startup’s mission is simple: help real people get cited by AI, not buried beneath it.

Media Contact
Company Name: geoCentric AI LLC
Contact Person: Pinny Rozen
Email: Send Email
Phone: 646-995-4013
Address:1820 Ave M #1079
City: Brooklyn
State: NY
Country: United States
Website: https://geocentric.ai/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From SEO to GEO: geocentric.ai Is Redefining Visibility in the AI Era

Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Spinal Muscular Atrophy Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
Spinal Muscular Atrophy companies working in the treatment market are Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others, are developing therapies for the Spinal Muscular Atrophy treatment

Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
In March 2025, Scholar Rock’s spinal muscular atrophy (SMA) treatment demonstrated improvements in muscle function among children under 12 in a key clinical study, yet the results failed to excite investors. The Phase III SAPPHIRE trial (NCT05156320) assessed the safety and effectiveness of apitegromab, a monoclonal antibody designed to enhance muscle growth by targeting and inhibiting the inactive forms of myostatin specifically within skeletal muscle.
In February 2025, A pilot clinical trial suggested that spinal cord stimulation (SCS) may help restore function in patients with spinal muscular atrophy (SMA) by gradually activating dormant motor neurons and enhancing leg muscle strength. Conducted by the University of Pittsburgh School of Medicine (NCT05430113), the study evaluated Medtronic’s Vectris SureScan device in three SMA patients. All participants demonstrated improved mobility, each increasing their distance in the six-minute walk test (6MWT)—a key indicator of muscle endurance—by at least 20 meters after three months of treatment.
In January 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing novel therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other serious diseases involving protein growth factors, has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab. This muscle-directed therapy is intended to deliver significant motor function improvement in individuals with SMA who are already receiving SMN-targeted treatments. The company also plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2025.
In January 2025, Analytics firm GlobalData has expressed a positive outlook on the future of Novartis’ gene therapy for spinal muscular atrophy (SMA), onasemnogene abeparvovec (OAV101 IT). The therapy may soon be accessible to a wider patient group, thanks to encouraging results from Novartis’ Phase III STEER trial (NCT05089656), in which the intrathecal version of the treatment successfully met its primary endpoint.
In November 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common diseases, announced updates on the development programs for taldefgrobep alfa in Spinal Muscular Atrophy (SMA) and obesity.
In November 2024, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other severe diseases driven by protein growth factors, has announced positive and statistically significant topline results from the pivotal Phase 3 SAPPHIRE trial. These findings highlight the potential of apitegromab to transform the standard of care for SMA patients.
In April 2024, Exegenesis Bio, a fast-expanding global leader in genetic medicine, has shared clinical efficacy and safety findings from its Phase 1/2 trial (EXG001-307) for Spinal Muscular Atrophy (SMA) Type I. The data was presented on May 8, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland (poster #627).

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. Motor neurons are nerve cells responsible for controlling voluntary muscle movement. When these motor neurons degenerate, muscles weaken and atrophy, leading to difficulties with movement, muscle weakness, and potentially life-threatening respiratory problems.

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

SKG 0201: Skyline Therapeutics
Spinal muscular atrophy gene therapy: Exegenesis Bio
BIIB115: Biogen
GC101: GeneCradle Inc.
EXG001-307: Hangzhou Jiayin Biotech Ltd
Apitegromab: Scholar Rock, Inc.
Talditercept alfa: Biohaven Pharmaceuticals, Inc

Spinal Muscular Atrophy Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Spinal Muscular Atrophy Molecule Type

Spinal Muscular Atrophy Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

Spinal Muscular Atrophy Assessment by Product Type
Spinal Muscular Atrophy By Stage and Product Type
Spinal Muscular Atrophy Assessment by Route of Administration
Spinal Muscular Atrophy By Stage and Route of Administration
Spinal Muscular Atrophy Assessment by Molecule Type
Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies

Some of the key companies in the Spinal Muscular Atrophy Therapeutics Market include:

Key companies developing therapies for Spinal Muscular Atrophy are – Genentech Inc, Chugai Pharmaceutical, Cytokinetics Inc., Ionis Pharmaceuticals Inc., Genzyme Corporation, Novartis International AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, PerkinElmer Inc., Pfizer Inc., UW Health, Novo Nordisk A/S, Cure SMA, Boehringer Ingelheim Gmbh, Biogen Inc, F. Hoffmann-La Roche AG, Catalyst Pharmaceutical, Salarius Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Isis Pharmaceuticals Inc., PTC Therapeutics, Natera Inc, AstraZeneca PLC, and others.

Spinal Muscular Atrophy Pipeline Analysis:

The Spinal Muscular Atrophy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spinal Muscular Atrophy drugs and therapies

Spinal Muscular Atrophy Pipeline Market Drivers

Increase in prevalence of Spinal Muscular Atrophy, increasing number of clinical trials and government funding for R&D are some of the important factors that are fueling the Spinal Muscular Atrophy Market.

Spinal Muscular Atrophy Pipeline Market Barriers

However, lack of public knowledge of this rare medical condition, cost associated with the treatment and other factors are creating obstacles in the Spinal Muscular Atrophy Market growth.

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

Coverage: Global
Key Spinal Muscular Atrophy Companies: Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others
Key Spinal Muscular Atrophy Therapies: SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others
Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Request for Sample PDF Report for Spinal Muscular Atrophy Pipeline Assessment and clinical trials

Table of Contents

1. Spinal Muscular Atrophy Report Introduction

2. Spinal Muscular Atrophy Executive Summary

3. Spinal Muscular Atrophy Overview

4. Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Spinal Muscular Atrophy Pipeline Therapeutics

6. Spinal Muscular Atrophy Late Stage Products (Phase II/III)

7. Spinal Muscular Atrophy Mid Stage Products (Phase II)

8. Spinal Muscular Atrophy Early Stage Products (Phase I)

9. Spinal Muscular Atrophy Preclinical Stage Products

10. Spinal Muscular Atrophy Therapeutics Assessment

11. Spinal Muscular Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Muscular Atrophy Key Companies

14. Spinal Muscular Atrophy Key Products

15. Spinal Muscular Atrophy Unmet Needs

16 . Spinal Muscular Atrophy Market Drivers and Barriers

17. Spinal Muscular Atrophy Future Perspectives and Conclusion

18. Spinal Muscular Atrophy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme

The rise of AI-driven Search prompts a shift in SEO strategy

““Appearing in Google search results is no longer enough,” says Bruno Díaz, Marketing Director at La Teva Web. “If your brand isn’t showing up in AI-generated answers, you’re missing a growing share of online visibility and influence.””

AI tools like ChatGPT and Gemini are reshaping how people search for information online. Barcelona-based agency La Teva Web is pioneering a new approach to SEO that helps companies gain visibility not just on Google, but also in generative AI responses.

Barcelona – May 19, 2025 – Generative AI is disrupting how users search and discover information online. As tools like ChatGPT, Google Gemini, Perplexity, and Microsoft Copilot become embedded in daily habits, the way people access content is shifting from traditional search engine listings to natural language answers. For businesses, this change marks a new frontier: being present in the response itself, not just ranking on a search page.

Leading this transformation is La Teva Web, a digital agency based in Barcelona and Google Partner Premier 2025, which has become a pioneer in SEO for AI. This emerging discipline — also known as LLMO (Large Language Model Optimization) — focuses on ensuring that a brand’s content is not only optimized for Google, but also clearly understood and cited by large language models.

The agency helps clients analyze their current visibility in AI tools, adapt their content to meet LLM expectations, and implement technical best practices such as structured data and llms.txt. The goal: to increase the likelihood of being cited as a trusted source in AI-generated answers.

“With more users turning to AI assistants to find answers, make decisions, or compare products, this isn’t a future trend — it’s today’s challenge,” says Díaz. “Businesses that act now will gain a competitive edge in a space that’s still underexploited.”

AI SEO

Media Contact
Company Name: La Teva Web SL
Contact Person: Francesc
Email: Send Email
Phone: 0034932503586
City: Barcelona
State: Catalonia
Country: Spain
Website: https://www.latevaweb.com/en/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The rise of AI-driven Search prompts a shift in SEO strategy

The Steam Team Launches Emergency Response Program with One-Click App for Commercial Accounts

Austin, TX – May 19, 2025 – The Steam Team of Austin, a leader in restoration, cleaning, and disaster recovery services for over 40 years, is proud to announce the launch of its Emergency Response Program (ERP), tailored specifically for commercial clients. This innovative offering is designed to provide fast, efficient, and stress-free emergency response through a powerful new one-click mobile app available on both iPhone and Android devices.

With a single tap, commercial clients can instantly notify The Steam Team of a fire, flood, mold issue, or other facility emergency — triggering a rapid deployment of certified technicians, project managers, and restoration crews, 24/7, 365 days a year.

“Time is everything in an emergency,” said David Marquardt, co-founder of The Steam Team. “We’ve spent decades responding to disasters across Central Texas. This new app allows us to mobilize in minutes instead of hours, helping our commercial partners minimize downtime, damage, and disruption.”

Built for Business Continuity

The Emergency Response Program was created with property managers, building engineers, healthcare facilities, hotels, schools, and multi-site commercial clients in mind. The goal is simple: simplify the emergency process and provide immediate access to trusted professionals when it matters most.

Through the app, clients can:

Report emergencies instantly via the One-Click Dispatch feature
Upload photos or videos of the damage
Share GPS-based location tagging
Connect with a dedicated account manager
Access a digital dashboard of response history, service reports, and ongoing claims

This real-time connection ensures The Steam Team can dispatch the right crews — equipped with the right gear — to the right location faster than ever before.

Always On. Always Ready.

Emergencies don’t wait for business hours, which is why The Steam Team’s ERP App is backed by a 24/7 command center. Whether it’s a burst pipe at midnight or smoke damage over a holiday weekend, certified restoration experts are always on call and ready to respond.

“It’s peace of mind in your pocket,” said Kristen Wells, Director of Commercial Accounts. “Our clients told us they wanted one number to call — or better yet, one button to push — when disaster strikes. We listened and built a solution that’s proactive, easy to use, and instantly effective.”

App Features at a Glance

One-Click Emergency Notification – Instantly notify The Steam Team’s emergency line with a single tap.
Photo & Video Uploads – Send real-time visuals to speed up assessment and mobilization.
GPS Location Sharing – Automatically share exact location to avoid delays or confusion.
Contact Directory – Keep your entire building response team connected in one place.
Service History & Documentation – Track every job, response time, and technician visit in one secure portal.
Custom Alerts & Notifications – Get real-time updates on job status, arrival times, and resolution reports.

A Trusted Partner for Commercial Property Owners

With decades of experience serving Texas businesses, The Steam Team has earned its reputation as the go-to emergency restoration service for companies that can’t afford delays. Their team of certified technicians is trained in water extraction, fire and smoke restoration, mold remediation, air duct cleaning, biohazard cleanup, and more.

By enrolling in the ERP, commercial clients also receive:

Priority dispatching
Free on-site inspections and pre-loss planning
Dedicated account management
Custom response protocols for each property
Access to trained CAT (catastrophe) response teams for large-scale losses

“We’re not just responders — we’re partners,” said Marquardt. “Our Emergency Response Program is about building relationships before the emergency happens, so we can act quickly, smartly, and in a way that protects your business and bottom line.”

Tailored to Your Industry

The ERP and app are fully customizable to serve clients across a wide range of industries:

Property Management – Ensure tenant safety and reduce vacancy downtime.
Healthcare – Maintain compliance and safety during emergency mitigation.
Hospitality – Keep your doors open and guest experience intact.
Retail – Minimize lost inventory and operational disruption.
Education – Provide safe, clean environments for students and staff.
Manufacturing/Warehousing – Protect assets, products, and supply chains.

Each account includes a pre-loss assessment and site walk-through, ensuring The Steam Team understands your property before an emergency ever occurs.

Designed & Developed in Texas

The ERP App was developed in partnership with a Texas-based software team, ensuring seamless performance on both iOS and Android platforms. It’s free to download and available exclusively to commercial clients who enroll in the Emergency Response Program.

Clients who sign up by July 31, 2025, will receive a free facility risk assessment, along with a custom digital response plan uploaded directly into the app.

“We believe in technology that serves people,” said Wells. “This app is not about replacing personal service — it’s about enhancing it with tools that help us do what we do best: respond fast and solve problems.”

About The Steam Team

Founded in 1983 in Austin, Texas, The Steam Team has grown into one of the most trusted names in disaster recovery and cleaning services across Central Texas. From commercial restoration to fine rug cleaning, the company combines old-school reliability with new-school technology to deliver results that matter. Locally owned and operated, The Steam Team is built on integrity, service, and commitment to community.

Media Contact
Company Name: The Steam Team Inc.
Contact Person: David Marquardt
Email: Send Email
Phone: 5124518326
Address:9901 Burnet Rd.
City: Austin
State: TX
Country: United States
Website: www.thesteamteam.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Steam Team Launches Emergency Response Program with One-Click App for Commercial Accounts

Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics

The Key Prurigo Nodularis Companies in the market include – Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others.

DelveInsight’s “Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast

Some of the key facts of the Prurigo Nodularis Market Report:

The Prurigo Nodularis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Incyte (Nasdaq: INCY) announced findings from its pivotal Phase 3 TRuE-PN clinical trial program, including the TRuE-PN1 and TRuE-PN2 studies, assessing the safety and efficacy of twice-daily ruxolitinib cream 1.5% (Opzelura®), a topical JAK1/2 inhibitor, in adult patients (18 years and older) with prurigo nodularis (PN).
In March 2025, Incyte (Nasdaq: INCY) announced positive topline results from its pivotal Phase 3 STOP-HS trial assessing the safety and efficacy of povorcitinib (INCB054707), an oral JAK1 inhibitor, in adults (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Povorcitinib, a selective JAK1 inhibitor, is also being investigated in Phase 3 trials for vitiligo and prurigo nodularis (PN) and in Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).
In February 2025, Galderma (SWX:GALD) announced that the European Commission has granted approval for Nemluvio in the EU to treat both moderate-to-severe atopic dermatitis and prurigo nodularis. Nemluvio is now authorized for subcutaneous use in patients aged 12 and older with moderate-to-severe atopic dermatitis requiring systemic therapy, as well as in adults with moderate-to-severe prurigo nodularis eligible for systemic treatment.
According to Morgan et al. (2022), the estimated prevalence of prurigo nodularis was recorded at 3.27 cases per 10,000 patients.
In 2023, among the 7MM, the United States had the largest diagnosed prevalent population of prurigo nodularis.
As per estimates, in Europe, the highest prevalence of age-specific cases of prurigo nodularis was observed in the 40-59 years age group, representing over 30% of the total cases in 2023.
DUPIXENT (dupilumab) stands as the sole therapeutic approved by the US FDA for the treatment of prurigo nodularis, with several other treatments currently undergoing development.
Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
The Prurigo Nodularis epidemiology based on gender analyzed that females are affected more as compared to males, in the case of Prurigo Nodularis
The Prurigo Nodularis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prurigo Nodularis pipeline products will significantly revolutionize the Prurigo Nodularis market dynamics.

Prurigo Nodularis Overview

Prurigo nodularis is a chronic skin condition characterized by the development of intensely itchy nodules or bumps on the skin. These nodules can vary in size and color and often appear on the arms, legs, or trunk. The itching associated with prurigo nodularis can be severe and persistent, leading to scratching and potentially causing further irritation and skin damage. The exact cause of prurigo nodularis is not fully understood, but it is believed to involve a combination of factors such as underlying skin conditions, nerve dysfunction, and immune system abnormalities.

Get a Free sample for the Prurigo Nodularis Market Report

https://www.delveinsight.com/report-store/prurigo-nodularis-market

Prurigo Nodularis Epidemiology

Prurigo Nodularis Epidemiology Segmentation:

The Prurigo Nodularis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Prurigo Nodularis
Prevalent Cases of Prurigo Nodularis by severity
Gender-specific Prevalence of Prurigo Nodularis
Diagnosed Cases of Episodic and Chronic Prurigo Nodularis

Download the report to understand which factors are driving Prurigo Nodularis epidemiology trends @ Prurigo Nodularis Epidemiology Forecast

Prurigo Nodularis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prurigo Nodularis market or expected to get launched during the study period. The analysis covers Prurigo Nodularis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Prurigo Nodularis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prurigo Nodularis Therapies and Key Companies

Nalbuphine ER: Trevi Therapeutics
Nemolizumab: Galderma
Vixarelimab(KPL-716): Genentech
Povorcitinib(INCB-54707): Incyte Corporation
Ruxolitinib Cream: Incyte Corporation
INCB054707: Incyte Corporation
serlopitant: Vyne Therapeutics Inc.
CC-10004: Celgene Corporation
Pimecrolimus: Novartis
Abrocitinib: Pfizer
Dupilumab SAR231893: Regeneron Pharma

Discover more about therapies set to grab major Prurigo Nodularis market share @ Prurigo Nodularis Treatment Market

Prurigo Nodularis Market Strengths

Novel drug formulations are unlocking the new market outlook and the potential to improve the QoL of patients suffering from the serious symptoms associated with chronic neurologically mediated conditions for which there are few, if any, treatment options.
Vixarelimab’s dual mechanism offers potential pruritus relief and nodule improvement in prurigo nodularis.

Prurigo Nodularis Market Opportunities

Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive the prurigo nodularis market.
Due to one approved drug in the market, there is a huge opportunity for the companies who are coming with novel emerging therapies.

Scope of the Prurigo Nodularis Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Prurigo Nodularis Companies: Trevi Therapeutics, Galderma, Genentech, Incyte Corporation, Vyne Therapeutics Inc., Celgene Corporation, Novartis, Pfizer, Regeneron Pharma, and others
Key Prurigo Nodularis Therapies: Nalbuphine ER, Nemolizumab, Vixarelimab(KPL-716), Povorcitinib(INCB-54707), Ruxolitinib Cream, INCB054707, serlopitant, CC-10004, Pimecrolimus, Abrocitinib, Dupilumab SAR231893, and others
Prurigo Nodularis Therapeutic Assessment: Prurigo Nodularis current marketed and Prurigo Nodularis emerging therapies
Prurigo Nodularis Market Dynamics: Prurigo Nodularis market drivers and Prurigo Nodularis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Prurigo Nodularis Unmet Needs, KOL’s views, Analyst’s views, Prurigo Nodularis Market Access and Reimbursement

To know more about Prurigo Nodularis companies working in the treatment market, visit @ Prurigo Nodularis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Prurigo Nodularis Market Report Introduction

2. Executive Summary for Prurigo Nodularis

3. SWOT analysis of Prurigo Nodularis

4. Prurigo Nodularis Patient Share (%) Overview at a Glance

5. Prurigo Nodularis Market Overview at a Glance

6. Prurigo Nodularis Disease Background and Overview

7. Prurigo Nodularis Epidemiology and Patient Population

8. Country-Specific Patient Population of Prurigo Nodularis

9. Prurigo Nodularis Current Treatment and Medical Practices

10. Prurigo Nodularis Unmet Needs

11. Prurigo Nodularis Emerging Therapies

12. Prurigo Nodularis Market Outlook

13. Country-Wise Prurigo Nodularis Market Analysis (2020–2034)

14. Prurigo Nodularis Market Access and Reimbursement of Therapies

15. Prurigo Nodularis Market Drivers

16. Prurigo Nodularis Market Barriers

17. Prurigo Nodularis Appendix

18. Prurigo Nodularis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics

Pennies on the Rise: HCTI, SWISF, ADHC, NCNA Gain Traction Amid LargeCap Uncertainty – More Stocks Inside

In a market defined by uncertainty and shifting investor sentiment, a select group of penny stocks is making waves across healthcare, cybersecurity, biotech, and digital infrastructure. Companies like Healthcare Triangle (NASDAQ: HCTI), Sekur Private Data Ltd. (OTCQB: SWISF | CSE: SKUR), American Diversified Holdings Corp. (OTC: ADHC), and NuCana plc (NASDAQ: NCNA), among others herein, are demonstrating resilience and innovation, positioning themselves for potential upside. As investors scan the under-the-radar landscape for growth catalysts, these emerging players are drawing fresh attention with breakthrough technologies, regulatory momentum, and expanding market reach.

Healthcare Triangle, Inc. (NASDAQ: HCTI) continues advancing healthcare transformation, recently achieving HITRUST r2 Certification for its CloudEz™, DataEz™, and readabl.AI platforms—signaling top-tier data protection and compliance standards. With a focus on digital agility, security, and interoperability, HCTI supports hospitals, pharma, and life sciences in leveraging cutting-edge cloud and data technologies.

Sekur Private Data Ltd. (OTCQB: SWISF | CSE: SKUR), a cybersecurity provider, is positioned in the $14.5B secure communications market growing at 19.8% CAGR. Its encrypted suite for email, messaging, and VPN services targets a booming $578.2B cybersecurity landscape expected by 2033. Sekur’s enterprise-grade upgrades and privacy-first model stand out in an increasingly data-vulnerable world. The company recently announced expansion efforts across eight African nations—Ethiopia, Zimbabwe, Angola, Uganda, Nigeria, Kenya, Ghana, and Mozambique—all among the most cyberattacked regions globally in early 2025.

American Diversified Holdings Corp. (OTC: ADHC) announces feedback progress on its Breakthrough Device Application, with Dr. Stephen C. Weber, MD leading its Medical Advisory Board. Dialogues with the FDA support upcoming regulatory steps. ADHC also signals forthcoming updates on strategic funding and partnerships.

NuCana plc (NASDAQ: NCNA), a clinical-stage biopharma firm, has priced a $7 million registered direct offering. The deal includes ADSs and two series of warrants, aimed at funding its cancer drug pipeline, general corporate use, and potential acquisitions. The offering is expected to close around May 7, 2025.

Additional Penny Stocks to Watch:

Yuengling’s Ice Cream Corp. (OTC: YCRM), now renamed Frequency Holdings, Inc., is shifting from nostalgia to next-gen tech. Modeled after Berkshire Hathaway and Alphabet, Frequency is building a multi-brand platform spanning AI, cybersecurity, and IT infrastructure. Its flagship brand, ReachOut, aims to dominate cybersecurity-first IT for SMBs, with future growth anticipated through new subsidiaries like TRUSTLESS.

Polyrizon Ltd. (NASDAQ: PLRZ), a development-stage biotech company, is innovating in nasal spray-based medical devices. Their hydrogel platform creates a protective shield in the nasal cavity, designed to guard against viruses and allergens by preventing contact with nasal epithelial tissue—a solution aimed at improving public health resilience.

Greenlane Holdings Inc. (NASDAQ: GNLN), a major U.S. distributor of vaporization products and consumption accessories, continues to serve both B2B and direct-to-consumer markets. Its extensive portfolio includes vaporizers, grinders, rolling papers, and premium packaging solutions, reinforcing its presence across the growing lifestyle and wellness space.

From AI-driven healthcare and secure data platforms to biotech breakthroughs and digital consumer goods, HCTI, SWISF, ADHC, NCNA, YCRM, PLRZ, and GNLN reflect the dynamic innovation unfolding across small-cap markets. Investors scanning the under-$1 and under-$5 range may find compelling growth narratives and speculative upside in these emerging plays.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pennies on the Rise: HCTI, SWISF, ADHC, NCNA Gain Traction Amid LargeCap Uncertainty – More Stocks Inside

Postoperative Pain Market to Expand Significantly by 2034, States DelveInsight Report | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Laboratories, Vertex Pharmaceutical

The Key Postoperative Pain Companies in the market include – Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others.

DelveInsight’s “Postoperative Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Postoperative Pain, historical and forecasted epidemiology as well as the Postoperative Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postoperative Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postoperative Pain Market Forecast

Some of the key facts of the Postoperative Pain Market Report:

The Postoperative Pain market size was valued ~USD 2,979 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In February 2025, Allay Therapeutics administered the first dose in its randomized Phase IIb registration trial evaluating ATX101, an investigational analgesic aimed at delivering prolonged pain relief after total knee replacement surgery.
In November 2024, PainReform is a clinical-stage specialty pharma company dedicated to improving existing therapies through reformulation. Its lead candidate, PRF-110, is a novel formulation of the local anesthetic ropivacaine, developed for managing postoperative pain. PRF-110 is a clear, oil-based, viscous solution administered directly into the surgical wound site before closure, delivering targeted and prolonged pain relief following surgery.
In January 2024, Heron Therapeutics announced that the FDA approved its supplemental New Drug Application (sNDA) for bupivacaine and meloxicam extended-release solution. The approval expands its indication to include soft tissue and orthopedic surgical procedures, specifically those where direct exposure to articular cartilage is avoided.
The postoperative pain market size in the United States was approximately USD 2,606 million in 2023 and is expected to grow, driven by rising awareness of the condition and the introduction of emerging therapies.
In 2023, the postoperative pain market size in EU4 and the UK was estimated at approximately USD 232 million, accounting for around 8% of the total market revenue in the 7MM.
Several leading postoperative pain companies are advancing their key drug candidates through various stages of clinical development, including IV Tramadol by Avenue Therapeutics, Opiranserin (VVZ-149) Injections by Vivozon, OCS-01 by Oculis, among others.
In 2023, the 7MM recorded approximately 67 million incident cases of postoperative pain. This number is projected to rise by 2034, driven by an increase in traffic accidents, trauma-related injuries, and the growing demand for pain management after surgeries.
In 2023, the US accounted for the highest proportion of incident postoperative pain cases, contributing approximately 60.41% of the total cases in the 7MM. Meanwhile, EU4 and the UK represented around 21.14%, while Japan accounted for approximately 18.43% of the total cases.
As per DelveInsight, in 2023, the estimated severity-specific incident cases of postoperative pain in France were approximately 1.2 million mild cases, 1.5 million moderate cases, and 0.8 million severe cases. These numbers are projected to rise by 2034 due to an increasing incidence of postoperative pain.
In 2023, the estimated severity-specific incident cases of postoperative pain in Germany were approximately 1.4 million mild cases, 1.7 million moderate cases, and 1 million severe cases. These figures are projected to rise throughout the forecast period (2024–2034).
In the UK, around 4,050,000 new cases of postoperative pain were reported in 2023.
Key Postoperative Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Postoperative Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
The Postoperative Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postoperative Pain pipeline products will significantly revolutionize the Postoperative Pain market dynamics.

Postoperative Pain Overview

Postoperative pain refers to pain that occurs after surgery. It is a common outcome following surgical procedures and can vary widely in intensity and duration depending on factors such as the type of surgery, individual pain tolerance, and the effectiveness of pain management strategies employed by healthcare providers.

Get a Free sample for the Postoperative Pain Market Report:

https://www.delveinsight.com/report-store/postoperative-pain-market

Postoperative Pain Epidemiology

Postoperative Pain Epidemiology Segmentation:

The Postoperative Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Number of Incident Cases of Postoperative Pain in the 7MM
Total Number of Surgical Procedures(inpatient and outpatient) in the 7MM
Severity-specific Incident Cases of Postoperative Pain in the 7MM

Download the report to understand which factors are driving Postoperative Pain epidemiology trends @ Postoperative Pain Epidemiology Forecast

Postoperative Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Pain market or expected to get launched during the study period. The analysis covers Postoperative Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Postoperative Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postoperative Pain Therapies and Key Companies

DEXTENZA (dexamethasone): Ocular Therapeutix
ZYNRELEF (bupivacaine and meloxicam): Heron Therapeutics
IV Tramadol: Avenue Therapeutics
TLC590: Taiwan Liposome Company (TLC)
TPU-006: Teikoku Pharma USA
CA-008: Concentric Analgesics
SVT-15473: Salvat Laboratories
VX-548: Vertex Pharmaceuticals
OCS-01: Oculis
N1539: Baudax Bio
SHR0410: Jiangsu HengRui Medicine
Ketorolac tromethamine: Darnitsa Pharma
AYX1: Adynxx, Inc.
EXPAREL: Pacira Pharma
Toragesic®: Apsen Farmaceutica S.A.
SABER-Bupivacaine: Durect
lyrica: Pfizer
VVZ-149: Vivozon, Inc.
Tapentadol (OS): Grünenthal GmbH
Percocet: Mallinckrodt
YM177: Astellas Pharma Inc
LMX4: Ferndale Laboratories, Inc.

Discover more about therapies set to grab major Postoperative Pain market share @ Postoperative Pain Treatment Market

Postoperative Pain Market Strengths

Drugs with a novel mechanism of action would provide new treatment options to the patients. For instance, SVT-15473 is a “superpotent” corticosteroid that has never been used before as eye drops.
Upcoming therapies are majorly non-opioids which are as effective, and this would reduce opioid dependence and other safety concerns associated with the current opioid medications.

Postoperative Pain Market Opportunities

Increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive this market.
Multimodal treatments can be prescribed to reduce the dependency on single-modal treatment. Launching such products will increase the potential ability to treat postoperative pain.

Scope of the Postoperative Pain Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Postoperative Pain Companies: Ocular Therapeutix, Heron Therapeutics, Avenue Therapeutics, Taiwan Liposome Company (TLC), Teikoku Pharma USA, Concentric Analgesics, Salvat Laboratories, Vertex Pharmaceuticals, Oculis, Baudax Bio, Jiangsu HengRui Medicine, Darnitsa Pharma, Adynxx, Inc., Pacira Pharma, Apsen Farmaceutica S.A., Durect, Pfizer, Vivozon, Inc., Grünenthal GmbH, Mallinckrodt, Astellas Pharma Inc, Ferndale Laboratories, Inc., and others
Key Postoperative Pain Therapies: DEXTENZA (dexamethasone), ZYNRELEF (bupivacaine and meloxicam), IV Tramadol, TLC590, TPU-006, CA-008, SVT-15473, VX-548, OCS-01, N1539, SHR0410, Ketorolac tromethamine, AYX1, EXPAREL, Toragesic®, SABER-Bupivacaine, lyrica, VVZ-149, Tapentadol (OS), Percocet, YM177, LMX4, and others
Postoperative Pain Therapeutic Assessment: Postoperative Pain current marketed and Postoperative Pain emerging therapies
Postoperative Pain Market Dynamics: Postoperative Pain market drivers and Postoperative Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Postoperative Pain Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Market Access and Reimbursement

To know more about Postoperative Pain companies working in the treatment market, visit @ Postoperative Pain Clinical Trials and Therapeutic Assessment

Table of Contents

1. Postoperative Pain Market Report Introduction

2. Executive Summary for Postoperative Pain

3. SWOT analysis of Postoperative Pain

4. Postoperative Pain Patient Share (%) Overview at a Glance

5. Postoperative Pain Market Overview at a Glance

6. Postoperative Pain Disease Background and Overview

7. Postoperative Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Postoperative Pain

9. Postoperative Pain Current Treatment and Medical Practices

10. Postoperative Pain Unmet Needs

11. Postoperative Pain Emerging Therapies

12. Postoperative Pain Market Outlook

13. Country-Wise Postoperative Pain Market Analysis (2020–2034)

14. Postoperative Pain Market Access and Reimbursement of Therapies

15. Postoperative Pain Market Drivers

16. Postoperative Pain Market Barriers

17. Postoperative Pain Appendix

18. Postoperative Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postoperative Pain Market to Expand Significantly by 2034, States DelveInsight Report | Taiwan Liposome Company, Teikoku Pharma USA, Durect, Pfizer, Vivozon, Salvat Laboratories, Vertex Pharmaceutical

The 3D Urology and Prostate Clinics Unveil Advanced Targeted Treatment Approach for Prostate Diseases

The 3D Urology and Prostate Clinics announce their specialized 3D Targeted Treatment, offering a unique and effective therapeutic option for patients suffering from various prostate conditions.

The 3D Urology and Prostate Clinics are pleased to announce the continued success and availability of their innovative treatment protocol for chronic prostatitis, BPH, and other prostate-related diseases. Utilizing a revolutionary approach based on precise diagnosis and targeted therapy, the clinics are transforming the landscape of prostate treatment and offering new hope to patients who have not found relief through conventional methods. This distinct methodology addresses the root causes of these complex conditions directly, leading to more favorable outcomes and improved quality of life for those affected. The 3D Urology and Prostate Clinics

Patients seeking specialized care for prostate issues can turn to The 3D Urology and prostate Clinic. This medical center is dedicated exclusively to diagnosing and treating a range of prostate conditions using its proprietary technology and treatment methods. The clinic’s expertise lies in accurately identifying the location, type, and quantity of pathogens and blockages within the prostate and surrounding areas. This meticulous diagnostic process is foundational to their treatment success, allowing for highly personalized and effective interventions that go beyond general antibiotics or surgical procedures. The clinic’s focus remains on providing a comprehensive understanding of the patient’s condition before initiating any therapy.

The core of the clinic’s approach is the 3D prostate Targeted Treatment. This innovative treatment involves precisely injecting natural, broad-spectrum antibiotics and unblocking medications directly into the identified lesion sites within the prostate gland and related areas. Unlike systemic treatments that may not reach effective concentrations in the infected or blocked areas, the 3D targeted treatment ensures that the necessary medications are delivered exactly where they are needed most. This targeted delivery maximizes therapeutic efficacy while minimizing potential side effects on the rest of the body, offering a more efficient and patient-friendly treatment experience compared to traditional, less localized methods.

The therapeutic process employed is known as 3D Targeted Therapy. This therapy focuses on clearing pathogens, eliminating blockages, and restoring normal function to the prostate and reproductive system. By directly addressing the specific pathological changes identified during the diagnosis, the 3D Targeted Therapy aims for a more complete and lasting recovery. Testimonials from patients highlight significant improvements in symptoms, and in many cases, the eradication of the underlying infection and inflammation. This method avoids invasive surgery and relies on the precise application of medicine to achieve healing and symptomatic relief, improving patients’ overall health and well-being.

The specialized approach at The 3D Urology and Prostate Clinics, incorporating precise diagnosis, targeted medication delivery, and comprehensive therapy, represents a significant advancement in the treatment of challenging prostate conditions. By focusing on the specific needs of each patient and directly addressing the pathology, the clinics are achieving remarkable results and providing a valuable alternative for those suffering from chronic or complex prostate issues.

About The 3D Urology and Prostate Clinics

The 3D Urology and Prostate Clinics specialize in the diagnosis and targeted treatment of chronic prostatitis, BPH, and other prostate diseases using their unique 3D Targeted Treatment approach for effective and lasting relief.

Media Contact
Company Name: The 3D Urology and Prostate Clinics
Contact Person: Miss Alisa Wang
Email: Send Email
Phone: +86-18673216429 (WhatsApp)
State: Hunan Province
Country: China
Website: http://www.3dprostatecure.com

EMEET Announces Major Breakthroughs in Webcam Innovation with New 4K Lineup for 2025

EMEET, a leading brand in audio and video communication technology, is proud to announce its latest innovation push in the webcam category with the launch of multiple 4K models. This milestone reflects EMEET’s deep commitment to redefining the webcam experience for professionals, creators, educators, and remote workers around the world.

Brand Positioning: Over 10 Years of Audio-Visual Expertise

With over a decade of R&D and product development in the audio and video space, EMEET has built a reputation for delivering reliable, intuitive, and high-performance tools that empower modern communication.

Brand Achievements: Leading Innovation, Broadest Reach

EMEET has emerged as the top-selling webcam brand on Amazon after Logitech, currently commanding approximately 20% market share in the online webcam segment, the brand dominates the 4K webcam space with undisputed sales leadership.

Its broad 4K portfolio—spanning use cases from office work and remote learning to livestreaming and content creation—represents the most comprehensive lineup by volume and performance on the platform. Setting a new benchmark for innovation, EMEET became the first brand globally to introduce a dual-camera design to 4K webcams with the launch of its Piko and Piko+ models, reinforcing its leadership in both market reach and technological advancement.

2025 Flagship 4K Products: Designed for Every Use Case

EMEET’s 2025 4K portfolio introduces targeted solutions tailored to creators, professionals, and casual users—offering class-leading performance and Amazon-proven appeal.

1. Piko Series – EMEET’s Flagship 4K Webcam with DualCamera

EMEET’s flagship Piko series stands as the brand’s hero lineup—anchored by the world’s first dual-camera AI-powered 4K webcam, setting a new benchmark for the 4K webcam for streaming category.

The Piko+ features a 1/2.55″ Sony sensor, AI-assisted autofocus, and a panda-inspired magnetic privacy cover, combining premium design with professional-grade performance. The Piko offers the same innovative dual-lens architecture and ultra-portable form factor, delivering core 4K streaming capabilities with a minimalist matte finish. Both models include three built-in microphones with adjustable sound modes and ensure plug-and-play ease across major platforms such as OBS, Zoom, and Microsoft Teams. Whether for livestreaming, beauty content creation, or professional presentations, the Piko series is a top-tier choice in the 4K Webcam for Streaming market.

2. S800 – EMEET’s Premium 4K Webcam for Professionals

As EMEET’s premium flagship, the S800 is a professional-grade 4K Webcam for Streaming featuring PDAF and TOF dual-focus technology with HDR imaging—delivering DSLR-comparable sharpness and lighting control in any environment.

With phase detection autofocus (PDAF) ensuring lightning-fast subject locking, and time-of-flight (TOF) depth sensing for smoother transitions and real-time distance adjustment, the S800 maintains flawless focus even during movement. HDR support enhances contrast and detail in both bright and low-light scenes, while a 1/2” SONY sensor and high-precision glass lenses deliver cinematic clarity. Whether for livestreaming, podcasting, or content creation, the S800 adapts to complex studio lighting and framing demands.

3. NOVA 4K and C960 4K – EMEET’s 4K Webcams with BestValue

Engineered as 4K upgrades to market’s top-selling 1080P models, the NOVA 4K and C960 4K represent the brand’s ultra-high value lineup—delivering premium clarity and core functionality at entry-level pricing.

Ideal for conference room setups, remote learning environments, professional creators, and budget-conscious streamers, both models feature crisp 3840×2160 resolution with automatic light correction, plug-and-play setup, and wide software compatibility including Zoom, Teams, Skype, and OBS. The NOVA 4K emphasizes vibrant color balance and smooth detail, while the C960 4K maintains the classic design of EMEET’s best-selling C960, now upgraded with 4K capability for enhanced clarity. These Webcam 4K models offer an accessible path to ultra-clear visuals without sacrificing reliability or ease of use.

With this comprehensive 4K strategy, EMEET continues to lead the webcam industry with breakthrough innovations that combine cutting-edge technology and broad user appeal. From the flagship Piko Series with its world-first dual-camera design, to the high-end S800 built for studio-level creators, and the NOVA 4K and C960 4K delivering unmatched value—EMEET offers a solution for every user, scenario, and budget. Whether you’re livestreaming, working remotely, or upgrading your everyday setup, EMEET invites you to experience the next generation of visual clarity.

Media Contact
Company Name: EMEET
Contact Person: Chloe Zheng
Email: Send Email
Country: United States
Website: https://emeet.afterservice.vip/